Purchase Order 75N92022P00006

The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $10,620 firm fixed price purchase order to Proteogenix, a for-profit manufacturer of biotechnology products and services. The contract provides additional laboratory screening services to support the development of novel gene therapy by the NHLBI's Center for Molecular Therapeutics and Bioanalytics (CMTB). This award is not associated with a larger contract vehicle and does not have...

The National Heart Lung and Blood Institute (NHLBI) awarded a $525,665.30 delivery order contract to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) for "Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities Cell Manufacturing and Process Development Services for RSA PCT0002-02: LOVO PACT Center Study." This task is part of the larger PACT-CPF master IDIQ contract vehicle. The contract has no set-aside designation...

This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...

The National Cancer Institute, a component of the Department of Health and Human Services' National Institutes of Health, awarded an $849,440 firm fixed price contract to the University of Oklahoma Health Sciences Center under the Prevent Preclinical Drug Development Program. The University will deliver on the stated objective of chemoprevention with aerosolized let-7 microRNA in mouse models of non-small cell lung cancer adenocarcinoma and squamous cell carcinoma. Two subcontracts were issued...

This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Promega Corporation for $132,961.50. The order is for Promega's cytochrome P450 screening assay systems to support the Tox21 drug screening program. The assay kits measure the activity of various CYP enzymes, which are critical for evaluating drug metabolism and toxicity. This award was sole-sourced to Promega as the sole...

The National Heart Lung and Blood Institute (NHLBI), a component of the Department of Health and Human Services, awarded a $25,900 firm fixed-price purchase order contract to QPS LLC, a minority-owned limited liability company, for the "Evaluation of R406 Levels in a Non-Human Primate Model of Bacterial Sepsis." This research and development contract, awarded on March 6, 2025, supports NHLBI's efforts to study bacterial sepsis progression and potential therapeutic interventions using...

This is a definitive, firm fixed-price contract awarded by the National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, to Hera Testing Laboratories Inc., a for-profit organization. The contract, valued at $293,728.00, is set aside for small businesses. The purpose of the contract is to contribute to studies of cancer health disparities by generating several patient-derived xenograft (PDX) models for non-small cell lung cancer (NSCLC) in an...

This is a firm-fixed price delivery order awarded by the National Cancer Institute, a civilian agency, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The award, valued at $607,113.00, is for a pre-clinical study to investigate the use of aerosolized bexarotene as a chemopreventive agent against the three major subtypes of lung cancer in mouse models. This work is being performed under the Preclinical Agent Development Assays 2012-2016 indefinite delivery...

This is a $83,800 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Promega Corporation. The award is to procure custom Promega assays and reagents, including the MTase-Glo Methyltransferase Assay, to support NCATS's Antiviral Program for Pandemics. The award is non-competitive as Promega's reagents are specifically engineered and optimized for NCATS's high-throughput screening and...

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $45,717 firm fixed price purchase order to Xenotech LLC, doing business as Sekisui-Xenotech, for the provision of cryopreserved human, mouse, and rat hepatocytes. The solicitation sought these hepatocytes for use in drug metabolism experiments to support the National Institute on Drug Abuse's malaria research project and understand drug metabolism in...